Skuldtech, AB Science to Develop CDx for Pancreatic Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Based on a new set of blood biomarkers, diagnostic development firm Skuldtech and pharma firm AB Science today said they plan to develop a companion diagnostic test for a molecule from AB Science for treating pancreatic cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.